MERIDEN, CT, United States

Protein Sciences Corporation

www.proteinscience.com
MERIDEN, CT, United States
SEARCH FILTERS
Time filter
Source Type

Dublin, April 18, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Seasonal Influenza Vaccine Market Size, Country Outlook, Vaccination Analysis, Pipeline Insights, Clinical Trials Statement, Deals Type, Regulatory, Price Trends, Competitive Strategies and Forecast, 2016 to 2022" drug pipelines to their offering. Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against seasonal influenza, introduction of quadrivalent influenza vaccines, increase in the size of the elderly population in most countries. The barriers limiting the growth of the influenza market include limited patient awareness regarding the threat of influenza and the importance of influenza vaccinations, high investment and strict regulations act as barriers for new entrants. Further, prudent analysis has been done on the competitor's part, where three major players grab major share of the seasonal influenza vaccine market by revenue. Sanofi Pasteur, GlaxoSmithKline(GSK), Seqirus, AstraZeneca and Protein Sciences Corporation are the key influencers with their products in the seasonal influenza vaccine market. Other emerging players such as Novavax, Daiichi-Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period. The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projection using a suitable set of assumptions and methodologies. It provides essential insights into seasonal influenza vaccine sales forecasts for the top seven countries, comprising the US, the UK, France, Italy, Spain, Germany and Japan until 2022. It also covers vaccination patterns and geographic distribution and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials, pipeline and promising vaccines in seasonal influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details. The report concludes with the profiles of major players in the seasonal influenza vaccine market such as Sanofi Pasteur, GSK, Sequirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook, and sales analysis of seasonal influenza vaccine market from 2011 to 2022. The report also entails major drivers and barriers of seasonal influenza vaccine market. Seven Major Markets(7MM) covered in the report are as follows: 1. United States 2. United Kingdom 3. France 4. Italy 5. Spain 6. Germany 7. Japan Major and Promising Vaccines covered in the report are as follows: 1. Fluzone High-Dose 2. Fluzone Quadrivalent 3. Intradermal (ID) Trivalent 4. Vaxigrip 5. Fluarix Quadrivalent 6. Flulaval Quadrivalent 7. Fluenz Tetra 8. FluMist Quadrivalent 9. Flublok 10. VN-100 11. M-001 12. VAX-2012Q 13. TAK-850 14. Flucelvax Quadrivalent 15. Afluria Quadrivalent 16. Agrippal 17. Fluad 18. Fluvirin 19. Fluvax Seasonal Influenza Vaccine Report is segmented into 10 points: 1: Introduction with Executive Summary 2: Forecasts data for the seasonal influenza vaccine market in the top seven countries. This point is divided into 4 segments. - Overall seasonal influenza vaccine market data from 2010 to 2022 - Overall number of persons vaccinated with seasonal influenza vaccine data from 2010 to 2022 - Seasonal influenza vaccine market share in the top seven countries data from 2010 to 2022 - Persons being vaccinated with influenza vaccine share in the top seven countries data from 2010 to 2022 3: Key market drivers and barriers in the seasonal influenza vaccine market 4: Detailed recent and forecasts for the seasonal influenza vaccine markets in the US, the UK, France, Italy, Spain, Germany and Japan, comprising of market size, total number of persons vaccinated, number of children vaccinated, number of 60+ years of age persons vaccinated, number of pregnant women vaccinated, number of chronic medical condition persons vaccinated, number of healthcare workers vaccinated and vaccination coverage 5: Detailed information on seasonal influenza vaccine production & distribution in United States. The information includes vaccine choices remain available for patients, providers, prices of a dose of vaccine, production, supply, and allocation by the major seasonal influenza vaccine manufacturers, seasonal influenza vaccine distribution & demand, seasonal influenza vaccine effectiveness, managing influenza with diagnostic resources, distribution method of seasonal influenza vaccination 6: Information about regulatory landscape including the approval process and an overview of the regulatory authorities in the United States, EU and Japan 7: Key M&A deals that took place in the seasonal influenza vaccine market between 2003 and 2015 and lists the major collaborations, licensing, exclusive and distribution agreements deals 8: Detailed pipeline influenza vaccines in various companies' pipelines with clinical development and early stage development vaccines 9: Detailed information of the recruiting clinical trials statement by phase, trial status, study sponsor name and study phase 10: Information on the key players in the market with business overview, product outlook and sales analysis of the seasonal influenza vaccine For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/jc66pd/seasonal


News Article | July 13, 2017
Site: marketersmedia.com

LONDON, UK / ACCESSWIRE / July 13, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for French drug maker and healthcare group Sanofi (NYSE: SNY), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=SNY. The Company announced on July 11, 2017, its plans to acquire the privately held vaccines biotech Company Protein Sciences for a total consideration of $750 million. With this deal, Sanofi is trying to step up its acquisition program after recently missing two large deals. For immediate access to our complimentary reports, including today's coverage, register for free now at: At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on SNY. Go directly to your stock of interest and access today's free coverage at: As per the agreement, Sanofi will make an upfront payment of $650 million and will pay the remaining $100 million upon achievement of certain milestones. Up till now, the Board of Directors of Protein Sciences and a majority of its shareholders have unanimously approved the acquisition. However, the deal is subject to customary regulatory approvals and is expected to close in Q3 2017. In October 2016, the US Food and Drug Administration (FDA) approved Protein Science's Flublok® Quadrivalent Influenza Vaccine (QIV). As of now, Flublok® is the only recombinant protein-based influenza vaccine approved by the FDA. David Loew, Executive Vice President and Head of Sanofi Pasteur (i.e. Sanofi's vaccines division) stated that the acquisition of Protein Sciences will help Sanofi broaden its flu portfolio with the addition of a non-egg based vaccine. Sanofi's vaccines portfolio already includes the four-in-one influenza vaccine Fluzone Quadrivalent, which the FDA approved in June 2013. The addition of Flublok®, however, brings a vaccine that can be used by those with egg allergies and has a shorter production timeline than tradition vaccines. All in all, this deal will strengthen Sanofi's position in the highly consolidated vaccine industry. Manon M.J. Cox, the Company's President, and Chief Executive Officer exclaimed that Protein Sciences has been actively looking for an opportunity to grow its business, especially in the US. He is hopeful that their vaccine, Flublok® will certainly benefit from Sanofi Pasteur's expertise in the field of influenza vaccines. Protein Sciences is a privately held biotech Company, which was established in 1983. It is headquartered in Meriden, Connecticut. Protein Sciences' mission is to save lives and improve health through the creation of innovative vaccines and biopharmaceuticals. Sanofi is a global healthcare leader, which discovers, develops, and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular; General Medicines and Emerging Markets; Sanofi Genzyme; Sanofi Pasteur; and Consumer Healthcare. On Wednesday, July 12, 2017, the stock closed the trading session at $48.89, rising 2.28% from its previous closing price of $47.80. A total volume of 1.06 million shares has exchanged hands. Sanofi's stock price surged 8.24% in the last three months, 19.10% in the past six months, and 15.04% in the previous twelve months. Furthermore, since the start of the year, shares of the Company have rallied 20.90%. The stock is trading at a PE ratio of 23.70 and has a dividend yield of 3.35%. At Wednesday's closing price, the stock's net capitalization stands at $124.66 billion. Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. LONDON, UK / ACCESSWIRE / July 13, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for French drug maker and healthcare group Sanofi (NYSE: SNY), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=SNY. The Company announced on July 11, 2017, its plans to acquire the privately held vaccines biotech Company Protein Sciences for a total consideration of $750 million. With this deal, Sanofi is trying to step up its acquisition program after recently missing two large deals. For immediate access to our complimentary reports, including today's coverage, register for free now at: At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on SNY. Go directly to your stock of interest and access today's free coverage at: As per the agreement, Sanofi will make an upfront payment of $650 million and will pay the remaining $100 million upon achievement of certain milestones. Up till now, the Board of Directors of Protein Sciences and a majority of its shareholders have unanimously approved the acquisition. However, the deal is subject to customary regulatory approvals and is expected to close in Q3 2017. In October 2016, the US Food and Drug Administration (FDA) approved Protein Science's Flublok® Quadrivalent Influenza Vaccine (QIV). As of now, Flublok® is the only recombinant protein-based influenza vaccine approved by the FDA. David Loew, Executive Vice President and Head of Sanofi Pasteur (i.e. Sanofi's vaccines division) stated that the acquisition of Protein Sciences will help Sanofi broaden its flu portfolio with the addition of a non-egg based vaccine. Sanofi's vaccines portfolio already includes the four-in-one influenza vaccine Fluzone Quadrivalent, which the FDA approved in June 2013. The addition of Flublok®, however, brings a vaccine that can be used by those with egg allergies and has a shorter production timeline than tradition vaccines. All in all, this deal will strengthen Sanofi's position in the highly consolidated vaccine industry. Manon M.J. Cox, the Company's President, and Chief Executive Officer exclaimed that Protein Sciences has been actively looking for an opportunity to grow its business, especially in the US. He is hopeful that their vaccine, Flublok® will certainly benefit from Sanofi Pasteur's expertise in the field of influenza vaccines. Protein Sciences is a privately held biotech Company, which was established in 1983. It is headquartered in Meriden, Connecticut. Protein Sciences' mission is to save lives and improve health through the creation of innovative vaccines and biopharmaceuticals. Sanofi is a global healthcare leader, which discovers, develops, and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular; General Medicines and Emerging Markets; Sanofi Genzyme; Sanofi Pasteur; and Consumer Healthcare. On Wednesday, July 12, 2017, the stock closed the trading session at $48.89, rising 2.28% from its previous closing price of $47.80. A total volume of 1.06 million shares has exchanged hands. Sanofi's stock price surged 8.24% in the last three months, 19.10% in the past six months, and 15.04% in the previous twelve months. Furthermore, since the start of the year, shares of the Company have rallied 20.90%. The stock is trading at a PE ratio of 23.70 and has a dividend yield of 3.35%. At Wednesday's closing price, the stock's net capitalization stands at $124.66 billion. Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


News Article | July 13, 2017
Site: www.accesswire.com

LONDON, UK / ACCESSWIRE / July 13, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for French drug maker and healthcare group Sanofi (NYSE: SNY), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=SNY. The Company announced on July 11, 2017, its plans to acquire the privately held vaccines biotech Company Protein Sciences for a total consideration of $750 million. With this deal, Sanofi is trying to step up its acquisition program after recently missing two large deals. For immediate access to our complimentary reports, including today's coverage, register for free now at: At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on SNY. Go directly to your stock of interest and access today's free coverage at: As per the agreement, Sanofi will make an upfront payment of $650 million and will pay the remaining $100 million upon achievement of certain milestones. Up till now, the Board of Directors of Protein Sciences and a majority of its shareholders have unanimously approved the acquisition. However, the deal is subject to customary regulatory approvals and is expected to close in Q3 2017. In October 2016, the US Food and Drug Administration (FDA) approved Protein Science's Flublok® Quadrivalent Influenza Vaccine (QIV). As of now, Flublok® is the only recombinant protein-based influenza vaccine approved by the FDA. David Loew, Executive Vice President and Head of Sanofi Pasteur (i.e. Sanofi's vaccines division) stated that the acquisition of Protein Sciences will help Sanofi broaden its flu portfolio with the addition of a non-egg based vaccine. Sanofi's vaccines portfolio already includes the four-in-one influenza vaccine Fluzone Quadrivalent, which the FDA approved in June 2013. The addition of Flublok®, however, brings a vaccine that can be used by those with egg allergies and has a shorter production timeline than tradition vaccines. All in all, this deal will strengthen Sanofi's position in the highly consolidated vaccine industry. Manon M.J. Cox, the Company's President, and Chief Executive Officer exclaimed that Protein Sciences has been actively looking for an opportunity to grow its business, especially in the US. He is hopeful that their vaccine, Flublok® will certainly benefit from Sanofi Pasteur's expertise in the field of influenza vaccines. Protein Sciences is a privately held biotech Company, which was established in 1983. It is headquartered in Meriden, Connecticut. Protein Sciences' mission is to save lives and improve health through the creation of innovative vaccines and biopharmaceuticals. Sanofi is a global healthcare leader, which discovers, develops, and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular; General Medicines and Emerging Markets; Sanofi Genzyme; Sanofi Pasteur; and Consumer Healthcare. On Wednesday, July 12, 2017, the stock closed the trading session at $48.89, rising 2.28% from its previous closing price of $47.80. A total volume of 1.06 million shares has exchanged hands. Sanofi's stock price surged 8.24% in the last three months, 19.10% in the past six months, and 15.04% in the previous twelve months. Furthermore, since the start of the year, shares of the Company have rallied 20.90%. The stock is trading at a PE ratio of 23.70 and has a dividend yield of 3.35%. At Wednesday's closing price, the stock's net capitalization stands at $124.66 billion. Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


News Article | July 11, 2017
Site: globenewswire.com

Paris, France - July 11, 2017 - Sanofi announced today it will acquire Protein Sciences, a privately held vaccines biotechnology company based in Meriden, Connecticut in the United States. Under the terms of the agreement, Sanofi will make an upfront payment of $650 million and pay up to $100 million upon achievement of certain milestones. Protein Sciences received approval from the US Food and Drug Administration (FDA) in October 2016 for their Flublok® Quadrivalent Influenza Vaccine (QIV). Flublok® is the only recombinant protein-based influenza vaccine approved by the FDA. "The acquisition of Protein Sciences will allow us to broaden our flu portfolio with the addition of a non-egg based vaccine," said David Loew, Sanofi Executive Vice President and Head of Sanofi Pasteur, Sanofi's vaccines division. "Protein Sciences was actively looking for an opportunity to grow its business, particularly in the US," said Manon M.J. Cox, President and Chief Executive Officer, Protein Sciences. "As part of Sanofi Pasteur, we expect our Flublok® influenza vaccine to benefit from Sanofi Pasteur's expertise in the field of influenza vaccines." The acquisition, which has been unanimously approved by the board of directors of Protein Sciences and a majority of Protein Sciences shareholders, is expected to close in the third quarter of 2017, subject to customary regulatory approvals. About Protein Sciences Protein Sciences is a privately held biotech company established in 1983 and headquartered in Meriden, CT. Protein Sciences' mission is to save lives and improve health through the creation of innovative vaccines and biopharmaceuticals. About Sanofi Pasteur Sanofi Pasteur produces vaccines against seasonal influenza on its four sites: Swiftwater (Pennsylvania, United States), Val de Reuil (France), Ocoyoacac (Mexico City, Mexico) and Shenzhen (China). About Sanofi Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the  ultimate outcome of such litigation,  trends in exchange rates and prevailing interest rates, volatile economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2016. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.


The publication notes that approximately 9,000 people aged 50 and older were enrolled and randomized in an efficacy study designed to compare Flublok Quadrivalent to a traditional quadrivalent vaccine. People who were given Flublok Quadrivalent were over 40% less likely to develop culture-confirmed influenza.  This data satisfies both pre-specified criteria for non-inferiority and superiority of Flublok over the traditional egg-based quadrivalent inactivated vaccine.  Flublok Quadrivalent was approved by the FDA in October 2016 and will be available nationwide in prefilled syringes for the upcoming flu season. "This study shows that Flublok® Quadrivalent, produced with modern recombinant technology can provide better protection against confirmed influenza-like illness among older adults than standard-dose quadrivalent influenza vaccine produced with traditional technology," said Lisa Dunkle MD, Chief Medical Officer of Protein Sciences. "We demonstrated statistically significantly better protection by Flublok based on considerably fewer people contracting the flu after vaccination with Flublok Quadrivalent. Today, we announce that these peer-reviewed results have been published in the highly respected New England Journal of Medicine. Furthermore, physicians are eligible for up to 1 hour AMA PRA category 1 CME credit for reading the article. Clearly, Flublok represents a major step forward in combating influenza on a global scale." Flublok is the only flu vaccine made without the use of eggs and therefore is not subject to the mutations that are sometimes introduced into the vaccine during the process of egg adaptation that can cause the traditional vaccines to be ineffective (see Skowronski et al. (2014) PLOS ONE 9(3), e92153). Flublok contains three times more active ingredients than traditional vaccines and produced significantly higher immune responses to the A strains of influenza (especially H3N2) in the Flublok Quadrivalent study. Furthermore, Flublok Quadrivalent is the first and only high antigen-content quadrivalent flu vaccine that with its high efficacy makes it ideal for older adults and those with a compromised immune system.  Flublok is highly purified and does not contain influenza virus, antibiotics, formaldehyde, preservatives, egg protein, latex, gluten or gelatin unlike other flu vaccines.  Flublok Quadrivalent is FDA approved for adults 18 and older. For more information about Flublok, please visit www.flublok.com. About Protein Sciences Protein Sciences is a world leader in vaccine development and protein production.  Our mission is our inspiration: to save lives and improve health through the creation of innovative vaccines and biopharmaceuticals. About Flublok® Flublok, the world's first recombinant protein-based vaccine for the prevention of seasonal influenza disease, is approved for all adults over 18 years. FDA approved the quadrivalent formulation ("Flublok Quadrivalent") in October 2016 that will be commercially available for everyone over 18 years for the 2017/18 influenza season.  Flublok is the only flu vaccine made in a 100% egg-free system using modern cell culture technology, making it unnecessary to use an infectious influenza virus, antibiotics or harsh chemicals (e.g., formaldehyde) in manufacturing.  Flublok is highly purified and does not contain any preservatives (e.g., thimerosal - a form of mercury), egg proteins, gelatin or latex.  In addition, Flublok contains three times more antigen than traditional flu vaccines (3x45mcg hemagglutinin protein versus 3x15mcg hemagglutinin protein).  In a 2014/15 post-marketing study of 9,000 adults 50 years and older, people who received Flublok were over 40% less likely to develop cell culture confirmed influenza than people who received a traditional flu vaccine.  Flublok is an exact copy of the influenza virus coat protein and is not subject to the egg-adapted mutations associated with low vaccine effectiveness (see Skowronski et al. (2014) PLOS ONE 9(3), e92153). Healthcare professionals in the U.S. wishing to order Flublok should contact one of the following distributors: Learn more at www.proteinsciences.com and www.flublok.com. Flublok Safety Information Flublok is approved for people 18 and older to prevent influenza disease.  The most common side effect from Flublok is pain at the site of injection. Headache, fatigue or muscle ache may occur.  Tell the doctor if you have ever experienced Guillain-Barré syndrome (severe muscle weakness) or have had a severe allergic reaction to any component of Flublok vaccine. Vaccination with Flublok may not protect all individuals. Please see the complete Package Insert available at www.flublok.com or call 203-686-0800 for more information. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/superior-protection-by-flublok-influenza-vaccine-in-seniors-documented-in-new-england-journal-of-medicine-300478298.html


Cox M.M.J.,Protein Sciences Corporation
Vaccine | Year: 2012

The baculovirus-insect cell expression system is a well known tool for the production of complex proteins. The technology is also used for commercial manufacture of various veterinary and human vaccines. This review paper provides an overview of how this technology can be applied to produce a multitude of vaccine candidates. The key advantage of this recombinant protein manufacturing platform is that a universal "plug and play" process may be used for producing a broad range of protein-based prophylactic and therapeutic vaccines for both human and veterinary use while offering the potential for low manufacturing costs. Large scale mammalian cell culture facilities previously established for the manufacturing of monoclonal antibodies that have now become obsolete due to yield improvement could be deployed for the manufacturing of these vaccines. Alternatively, manufacturing capacity could be established in geographic regions that do not have any vaccine production capability. Dependent on health care priorities, different vaccines could be manufactured while maintaining the ability to rapidly convert to producing pandemic influenza vaccine when the need arises. © 2012 Elsevier Ltd.


Patent
Protein Sciences Corporation | Date: 2013-03-15

The present invention relates to methods of improving the stability and maintaining the potency of recombinant hemagglutinin formulations, in particular, recombinant influenza hemagglutinin (rHA). In particular, Applicants have shown that the stability of rHA formulations may be significantly improved by mutating cysteine residues or by formulating with a reducing agent and sodium citrate.


Grant
Agency: Department of Defense | Branch: Army | Program: SBIR | Phase: Phase I | Award Amount: 100.00K | Year: 2015

In this proposal, Protein Sciences Corporation proposes to develop a bivalent, recombinant protein based adenovirus vaccine to protect against serotypes 4 and 7, based on our proprietary platform technology of baculovirus expression vector system (BEVS) and insect cells. We propose the hexon protein as the target antigen as it is considered the primary target for neutralizing antibodies generated against adenovirus, and protection from adenovirus disease is associated with the presence of serotype specific serum neutralizing antibodies. The use of recombinant baculovirus to express foreign proteins in insect cells has been well characterized, and has matured into a commercial manufacturing technology. This technology will allow rapid incorporation of additional serotypes if the need arises. The fundamental high level objective of Phase I is to demonstrate the feasibility of expression and purification of the hexon proteins based on the BEVS and insect cell platform technology, and to provide preliminary stability assessment on the candidate product. The resulting proof-of-concept data should support the future objectives in Phase II for pilot scale process development, immunogenicity studies in small animals, toxicology study, and other preparation activities related to filing an Investigational New Drug (IND) application with the FDA for Phase I clinical trial.


Grant
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase II | Award Amount: 1.20M | Year: 2014

DESCRIPTION provided by applicant Lung cancer is the leading cause of cancer death in the United States and is responsible for more deaths each year than breast prostate colon hepatic renal and skin cancers combined Viewed in economic terms in the United States the value of life lost from lung cancer deaths in the year was more than $ billion which is estimated to rise to more than $ billion in Because of the immense health care and economic burden imposed by lung cancer new therapy strategies that improve patient outcomes will lead to very a significant impact Collaborators at Chesapeake PERL Inc C PERL and UCLA Laboratory of Leonard Rome have identified and characterized a unique nanoparticle structure called a vault that is highly stable and found ubiquitously in all higher eukaryotes The vault shell is entirely composed of multiple copies of a single protein called Major Vault Protein MVP MVP can be readily engineered to permit attachment of other agents including promising cancer therapeutics like the chemokine CCL CCL is a lymphoid chemokine that is chemoattractant for mature dendritic cells DCs and naive and memory T cells Preclinical studies in a lung cancer animal model have demonstrated that intratumoral administration of CCL gene modified dendritic cells led to tumor eradication Vaults have been expressed at Chesapeake PERL Inc C PERL to very high levels using the PERLXpress protein expression platform The unique and powerful system uses recombinant baculovirus expression in whole insects in an automated platform to generate high protein yields cost effectively MVP and CCL fused to a vault packaging peptide called INT are readily expressed and correctly assembled to form CCL Vault nanoparticles The particle has been shown to slowly release its chemokine payload over several days Hundreds of milligrams of highly purified CCL Vaults can be readily prepared and stably stored in a lyophilized state for future therapeutic evaluation and testing Continued development proposed in this Phase II application will support advanced development pre clinical safety evaluation including toxicology efficacy and formulation leading to IND preparation to support future GCMP product manufacture Intratumoral administration of recombinant CCL vaults derived from baculovirus infection of whole insects will be tested in a preclinical animal model for destruction of tumors The CCL Vault is proposed to circumvent autologous DC preparation minimize batch to batch variability and allow for comparability and standardization so that the particle can be used as an off the shelf reagent for advanced non small cell lung cancer NSCLC PUBLIC HEALTH RELEVANCE This project is relevant to treatment of common causes of death and disability due to lung cancer The research will support continued development of a candidate therapy using a recombinant version of naturally occurring human vault protein in combination with CCL antitumor agent The combination technologies may result in a drug that targets lung cancer demonstrating a large scale low cost reproducible therapy This is a potentially disruptive approach that can revolutionize the lung cancer field and may be applied to other cancers


Patent
Protein Sciences Corporation | Date: 2011-10-12

A method of preparing a recombinant influenza vaccine using DNA technology is provided. The resulting vaccine is a multivalent, preferably trivalent, influenza vaccine based on a mixture of recombinant hemagglutinin antigens cloned from influenza viruses having epidemic potential. The recombinant hemagglutinin antigens are full length, uncleaved (HAO), glycoproteins produced from baculovirus expression vectors in cultured insect cells and purified under non-denaturing conditions. In the preferred embodiment, the cloned HA genes are then modified by deletion of the natural hydrophobic signal peptide sequences and replacing them with a new baculovirus chitinase signal peptide. A general approach for the efficient extraction and purification of recombinant HA protein produced in insect cells is also disclosed for the purification of rHA proteins from A sub-types and B type influenza viruses.

Loading Protein Sciences Corporation collaborators
Loading Protein Sciences Corporation collaborators